Status:
COMPLETED
Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes
Lead Sponsor:
F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Conditions:
Covid19
Liver Diseases
Eligibility:
All Genders
19+ years
Phase:
PHASE4
Brief Summary
Of patients admitted to an internal medicine ward with internistic diagnosis/es together with COVID-19, substantial proportion has elevated liver enzymes. silymarin / silibinin (milk thistle extract) ...
Detailed Description
According to the Bosch-Barrera et al. paper of 2021, silibinin in a daily dose of more than 1000 mg could improve clinical course of COVID-19 by its dual action: 1.direct inhibition of SARS-CoV-2 repl...
Eligibility Criteria
Inclusion
- consecutive, adult, admitted to an internal medicine ward with internistic diagnosis, together with COVID-19, and elevated liver enzymes (any of AST, ALT, GGT, ALP), provided written informed consent
Exclusion
- too sick - terminal illness (no potential for recovery); critical condition on admission requiring immediate tracheal intubation; or any extra-pulmonary organ failure; completely vaccinated against COVID19.
Key Trial Info
Start Date :
March 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04816682
Start Date
March 17 2021
End Date
December 30 2021
Last Update
August 3 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
F.D.Roosevelt Teaching Hospital
Banská Bystrica, Slovakia, 97401
2
University Hospital Bratislava
Bratislava, Slovakia, 82101